Skip to main content
Clinical Trials/EUCTR2012-002107-17-CZ
EUCTR2012-002107-17-CZActive, not recruitingPhase 1

International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours - Euro Ewing 2012

niversity of Birmingham0 sites600 target enrollmentStarted: June 3, 2015Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
600

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Randomisation R1:
  • * Any histologically and genetically confirmed ESFT of bone or soft
  • tissue, or round cell sarcomas which are 'Ewing's-like' but negative for EWSRl gene rearrangement
  • *Age >2 years and <50 years (from second birthday to 49 years 364
  • days) at the date of randomisation
  • *Randomisation = 45 days after diagnostic biopsy/surgery
  • * Patient assessed as medically fit to receive the treatment in either of
  • the Rl treatment arms
  • * No prior treatment for ESFT other than surgery
  • * Documented negative pregnancy test for female patients of
  • childbearing potential
  • * Patient agrees to use contraception during therapy and for 12 months
  • after last trial treatment (females) or 6 months after last trial treatment
  • (males), where applicable
  • *Written informed consent from the patient and/or the parent/legal
  • Randomisation 2:
  • *Age >5 years (from fifth birthday) at date of randomisation
  • * Localised tumour
  • * Metastatic disease and/or regional lymph node(s) involvement only at
  • diagnosis and at least partial response of the metastases and/or
  • regional lymph node(s)
  • * Consolidation chemotherapy as per protocol intended
  • * Patient assessed as medically fit to receive zoledronic acid if allocated
  • *Written informed consent from the patient and/or the parent/legal
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 470
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 130
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

Exclusion Criteria

  • Randomisation Rl
  • Contra-indication to the treatment in either of the Rl treatment arms
  • Second malignancy
  • Pregnant or breastfeeding women
  • Follow-up not possible due to social, geographic or psychological
  • Randomisation 2:
  • * History of dental surgery (extraction or jaw surgery) in the 6 months
  • preceding the start of zoledronic acid treatment, or planned dental
  • surgery within the treatment period or within 6 months after the end of
  • * Ewing's tumour of the maxilla or of the mandible
  • * Progression of the primary tumour or appearance of new lesions

Investigators

Similar Trials